Abstract
Daclizumab beta is a humanized monoclonal antibody that binds to CD25 and selectively inhibits high-affinity IL-2 receptor signaling. As a former treatment for relapsing forms of multiple sclerosis (RMS), daclizumab beta induces robust expansion of the CD56<sup>bright</sup> subpopulation of NK cells that is correlated with the drug's therapeutic effects. As NK cells represent a heterogeneous population of lymphocytes with a range of phenotypes and functions, the goal of this study was to better understand how daclizumab beta altered the NK cell repertoire to provide further insight into the possible mechanism(s) of action in RMS. We used mass cytometry to evaluate expression patterns of NK cell markers and provide a comprehensive assessment of the NK cell repertoire in individuals with RMS treated with daclizumab beta or placebo over the course of 1 year. Treatment with daclizumab beta significantly altered the NK cell repertoire compared to placebo treatment. As previously reported, daclizumab beta significantly increased expression of CD56 on total NK cells. Within the CD56<sup>bright</sup> NK cells, treatment was associated with multiple phenotypic changes, including increased expression of NKG2A and NKp44, and diminished expression of CD244, CD57, and NKp46. These alterations occurred broadly across the CD56<sup>bright</sup> population, and were not associated with a specific subset of CD56<sup>bright</sup> NK cells. While the changes were less dramatic, CD56<sup>dim</sup> NK cells responded distinctly to daclizumab beta treatment, with higher expression of CD2 and NKG2A, and lower expression of FAS-L, HLA-DR, NTB-A, NKp30, and Perforin. Together, these data indicate that the expanded CD56<sup>bright</sup> NK cells share features of both immature and mature NK cells. These findings show that daclizumab beta treatment is associated with unique changes in NK cells that may enhance their ability to kill autoreactive T cells or to exert immunomodulatory functions.
Introduction
Multiple Sclerosis (MS) is characterized by the immune system mistakenly attacking the central nervous system. Daclizumab beta, a monoclonal antibody that blocks the CD25 receptor, was known to be effective because it caused a massive expansion of a specific subset of Natural Killer (NK) cells, specifically the CD56<sup>bright</sup> population. However, the exact identity and functional state of these expanded cells remained unclear. This study sought to determine if the drug simply increased the number of existing cells or if it induced a novel phenotypic state that could explain its therapeutic efficacy.
Methods
The researchers utilized cryopreserved peripheral blood mononuclear cells (PBMCs) from the SELECT and DECIDE clinical trials, including 30 daclizumab beta-treated individuals, 17 placebo-treated individuals, and 16 healthy donors. Samples were analyzed at baseline, 24 weeks, and 52 weeks.
To profile the immune system at high resolution, the team employed Mass Cytometry (CyTOF), which uses heavy metal isotopes to measure over 40 markers simultaneously on single cells. Data analysis was performed using CytoGLMM, an R package for statistical modeling that accounts for inter-subject variation, and unsupervised clustering algorithms (FlowSOM/CATALYST) to identify cell subsets without prior bias.
Results
Robust Expansion and Global Phenotypic Shift
Treatment with daclizumab beta significantly increased the frequency of CD56<sup>bright</sup> NK cells over the course of one year, confirming previous clinical observations with high precision. Unsupervised UMAP analysis demonstrated that this was not the expansion of a niche subset, but rather a broad, global shift in the phenotype of the entire CD56<sup>bright</sup> population.
The "Hybrid" Phenotypic Fingerprint
Detailed analysis revealed that the expanded CD56<sup>bright</sup> cells adopted a unique "hybrid" state. They expressed high levels of NKG2A (typically an immature marker) and NKp44, while simultaneously showing increased levels of mature effector markers like CD16 and Perforin. Conversely, expression of CD244, CD57, and NKp46 decreased. This signature suggests the cells are "primed" hybrids, combining regulatory and cytotoxic features.
CD56<sup>dim</sup> Response
Even the mature CD56<sup>dim</sup> NK cells, which were not the primary target, showed significant changes. They increased expression of CD2 and NKG2A but decreased levels of FAS-L, HLA-DR, and Perforin. These findings indicate that daclizumab beta causes a complex rebalancing of the entire circulating NK cell repertoire.
Discussion
This study provides a high-resolution blueprint of the therapeutic NK cell repertoire in MS. The discovery of a stable, hybrid CD56<sup>bright</sup> phenotype suggests these cells may be uniquely equipped to eliminate autoreactive T cells. Although daclizumab beta was withdrawn from the market in 2018 due to safety concerns, understanding this specific "hybrid" state offers a clear target for future drug development. Future work must bridge the gap between these phenotypic observations and functional killing assays to confirm the exact mechanism of action and investigate potential links to the drug's side effects.
Summary updated